Becton, Dickinson and Company (BDX) Earnings Call Transcripts

Becton, Dickinson and Company's Latest Earnings Call - September 9, 2026

In the fiscal Q3 2026 earnings call for Becton, Dickinson and Company (BDX), management reported a 4.4% organic growth, with 90% of the portfolio achieving high single-digit growth. The company raised its guidance for the high end of low single-digit growth for the full year, indicating confidence despite anticipated deceleration in Q4 due to the Alaris product line. Management emphasized ongoing improvements in margins and a strong pipeline of innovations, setting a positive tone for future growth.

Reported metrics

Guidance from management

Management maintained guidance for low single-digit growth for FY 2027, emphasizing that this reflects a prudent approach considering the Alaris headwind and other dynamics in the business.

What management said

Yes, I think long term, that it's a -- let's call it an accretive business to BD long term. We even said last quarter, the business grew in the teens ex vaccines, right? Continued very strong double-digit growth in biologics well past -- way past 20% growth in GLP-1s. So continued strong performance there, strong pipeline. We've got presence in the right molecule mix that we want. So more to come there, but...

And similar to just complement similar to China, Vaccines is becoming a smaller part of the business as well. So we came from like $450 million towards $300 million of revenue. in total. So it's becoming a smaller part of the business. We are having good signs that we are not going to see a headwind of the same magnitude, but it's becoming a smaller part of the business as well.

What analysts pressed on

Analysts expressed concerns about the ongoing challenges in the Chinese market and the impact of the Alaris product line on future growth. There were also questions regarding the sustainability of vaccine revenue and how it would affect overall performance in FY 2027.

Main topics on the call

• Organic Growth Performance — Becton, Dickinson reported a 4.4% organic growth in Q3, with management noting that '90% of the portfolio growing high single digits.' This reflects strong performance across their focused portfolio, which is expected to...
• Guidance Update — Management raised the guidance for the high end of low single-digit growth for the full fiscal year, citing confidence from year-to-date results. They noted, 'We have been delivering on our commitments and exceeding,' wh...
• Alaris Product Line Dynamics — Management indicated that the Alaris product line will exert a 200 basis point headwind in Q4 due to its prior year performance. They stated, 'You can expect that as we think about our outlook for 2017,' signaling a temp...
• Margin Improvement — Management expects a sequential ramp in margins of 300-400 basis points in Q4, driven by strong performance in growth drivers and operational excellence. They mentioned, 'We have high visibility of that,' indicating conf...

Read the full Becton, Dickinson and Company transcript (September 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 83 Becton, Dickinson and Company earnings call transcripts on record, spanning January 14, 2020 to September 9, 2026. Based on this history, Becton, Dickinson and Company reports quarterly. The most recent call on file is dated September 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

BDX

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

83

First call

January 14, 2020

Most recent

September 9, 2026

Reporting cadence

quarterly